A Mayo Clinic study has found that imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans. "These are early results but they are promising, says the study's lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. "Some patients in our clinical ...
Read MoreYou have just read an article categorized health
titled Mayo Clinic Research Suggests Drug Induces Clinical Remissions in Myelofibrosis.
Written by:
editor - Sunday, December 8, 2013
There are currently no comments for "Mayo Clinic Research Suggests Drug Induces Clinical Remissions in Myelofibrosis"
Post a Comment